Market Snapshot
  • U.S.
  • Europe
  • Asia
Ticker Volume Price Price Delta
DJIA 16,408.54 -16.31 -0.10%
S&P 500 1,864.85 2.54 0.14%
NASDAQ 4,095.52 9.29 0.23%
Ticker Volume Price Price Delta
STOXX 50 3,155.81 16.55 0.53%
FTSE 100 6,625.25 41.08 0.62%
DAX 9,409.71 91.89 0.99%
Ticker Volume Price Price Delta
NIKKEI 14,516.27 98.74 0.68%
TOPIX 1,173.37 6.78 0.58%
HANG SENG 22,760.24 64.23 0.28%

Financial Results, Regulatory Approval, Stock Price Update, and Conference Participation - Research Report on Hologic, Edwards



  Financial Results, Regulatory Approval, Stock Price Update, and Conference
  Participation - Research Report on Hologic, Edwards Lifesciences, Hospira,
                             PAREXEL, and Sirona

Editor Note: For more information about this release, please scroll to bottom.

PR Newswire

NEW YORK, November 12, 2013

NEW YORK, November 12, 2013 /PRNewswire/ --

Today, Analysts' Corner announced new research reports highlighting Hologic,
Inc. (NASDAQ: HOLX

Edwards Lifesciences Corp (NYSE: EW), Hospira, Inc. (NYSE: HSP), PAREXEL
International Corporation (NASDAQ: PRXL), and Sirona Dental Systems, Inc.
(NASDAQ: SIRO). Today's readers may access these reports free of charge -
including full price targets, industry analysis and analyst ratings - via the
links below.

Hologic, Inc. Research Report

On November 7, 2013, Hologic, Inc. (Hologic) announced that the U.S. Food and
Drug Administration (FDA) has approved the Aptima HPV 18/45 genotype assay for
use on the Company's fully automated Panther system. According to the Company,
it is the first test to be approved by FDA for genotyping human papillomavirus
(HPV) types 16, 18 and/or 45. The Aptima HPV 16 18/45 genotype assay is
performed using Hologic's ThinPrep liquid cytology specimen and is intended to
be tested from the same sample that has already received Aptima HPV assay
positive results. "The addition of the Aptima HPV 16 18/45 genotype assay to
the Panther menu further extends the capability of low- to high-volume
laboratories to run multiple tests from a single specimen, on a
cost-effective, highly flexible and fully automated molecular testing
platform," said Rohan Hastie, Ph.D., Hologic's Group's Vice President -
Diagnostics. The Full Research Report on Hologic, Inc. - including full
detailed breakdown, analyst ratings and price targets - is available to
download free of charge at:

[http://www.analystscorner.com/r/full_research_report/d132_HOLX]

--

Edwards Lifesciences Corp Research Report

On November 7, 2013, Edwards Lifesciences Corp's (Edwards Lifesciences) stock
rose 1.68% to close the day $63.61. Over the past three trading sessions,
Edward Lifesciences' stock rallied 0.57%, compared to the Dow Jones Industrial
Average Index, which fell 0.29% during the same period. The Full Research
Report on Edwards Lifesciences Corp - including full detailed breakdown,
analyst ratings and price targets - is available to download free of charge
at:

[http://www.analystscorner.com/r/full_research_report/48b8_EW]

--

Hospira, Inc. Research Report

On November 6, 2013, Hospira, Inc. (Hospira) reported its Q3 2013 financial
results with net sales of $1.0 billion, up 1.4% YoY. Hospira's adjusted income
from operations increased 8.3% YoY to $122 million in Q3 2013, driven by
favorable product mix compared to Q3 2012 as well as supply recovery in the
United Sates, which more than offset increase in selling, general and
administrative expense on YoY basis. Commenting on the results, Hospira's CEO
F. Michael Ball stated, "The third quarter was one of continued progress in
several areas. We were especially pleased to receive European approval in the
quarter of our biosimilar infliximab, Inflectra™ - the first monoclonal
antibody biosimilar to be approved in Europe. We are also seeing continued
demand for the new premix versions of our branded sedation agent, Precedex™.
At the same time, we have made meaningful advances in both our supply recovery
efforts and quality-improvement initiatives. We believe our progress across
these fronts is positioning Hospira for a stronger, more competitive future,
which we believe will provide sustainable, long-term growth and value to our
shareholders." The Full Research Report on Hospira, Inc. - including full
detailed breakdown, analyst ratings and price targets - is available to
download free of charge at:

[http://www.analystscorner.com/r/full_research_report/1f43_HSP]

--

PAREXEL International Corporation Research Report

On November 7, 2013, PAREXEL International Corporation (PAREXEL) announced its
participation at the upcoming Goldman Sachs Emerging Growth Conference, to be
held in New York, on Thursday, November 14, 2013 at 11:20 a.m. ET. The Company
informed that during the presentation PAREXEL's Chairman and CEO, Josef von
Rickenbach will discuss about the business developments of the Company.
According to the Company, a live webcast of the presentation will be available
at PAREXEL's website. The Full Research Report on PAREXEL International
Corporation - including full detailed breakdown, analyst ratings and price
targets - is available to download free of charge at:

[http://www.analystscorner.com/r/full_research_report/067b_PRXL]

--

Sirona Dental Systems, Inc. Research Report

On November 7, 2013, Sirona Dental Systems, Inc.'s (Sirona) stock ended the
day 0.89% lower to $71.65. Over the past three trading sessions, Sirona's
stock fell 1.12% compared to the NASDAQ composite index, which declined 2.01%
during the same period. The Full Research Report on Sirona Dental Systems,
Inc. - including full detailed breakdown, analyst ratings and price targets -
is available to download free of charge at:

[http://www.analystscorner.com/r/full_research_report/08e7_SIRO]

----

EDITOR NOTES:

 1. This is not company news. We are an independent source and our views do
    not reflect the companies mentioned.
 2. Information in this release is fact checked and produced on a best efforts
    basis and reviewed by Namrata Maheshwari, a CFA charterholder. However, we
    are only human and are prone to make mistakes. If you notice any errors or
    omissions, please notify us below.
 3. This information is submitted as a net-positive to companies mentioned, to
    increase awareness for mentioned companies to our subscriber base and the
    investing public.
 4. If you wish to have your company covered in more detail by our team, or
    wish to learn more about our services, please contact us at
    pubco@EquityNewsNetwork.com.
 5. For any urgent concerns or inquiries, please contact us at
    compliance@EquityNewsNetwork.com.
 6. Are you a public company? Would you like to see similar coverage on your
    company? Send us a full investors' package to
    research@EquityNewsNetwork.com for consideration.

COMPLIANCE PROCEDURE

Content is researched, written and reviewed on a best-effort basis. This
document, article or report is prepared and authored by Equity News Network.
An outsourced research services provider represented by Namrata Maheshwari,
CFA, has only reviewed the information provided by Equity News Network in this
article or report according to the Procedures outlined by Equity News Network.
Equity News Network is not entitled to veto or interfere in the application of
such procedures by the outsourced provider to the articles, documents or
reports, as the case may be.

NOT FINANCIAL ADVICE

Equity News Network makes no warranty, expressed or implied, as to the
accuracy or completeness or fitness for a purpose (investment or otherwise),
of the information provided in this document. This information is not to be
construed as personal financial advice. Readers are encouraged to consult
their personal financial advisor before making any decisions to buy, sell or
hold any securities mentioned herein.

NO WARRANTY OR LIABILITY ASSUMED

Equity News Network is not responsible for any error which may be occasioned
at the time of printing of this document or any error, mistake or shortcoming.
No liability is accepted by Equity News Network whatsoever for any direct,
indirect or consequential loss arising from the use of this document. Equity
News Network expressly disclaims any fiduciary responsibility or liability for
any consequences, financial or otherwise arising from any reliance placed on
the information in this document. Equity News Network does not (1) guarantee
the accuracy, timeliness, completeness or correct sequencing of the
information, or (2) warrant any results from use of the information. The
included information is subject to change without notice.

CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA
Institute.

AnalystsCorner.com

SOURCE Analysts' Corner

Contact: Joe Thomas, CONTACT PHONE: +1-310-496-8071 (North America)
Sponsored Links
Advertisement
Advertisements
Sponsored Links
Advertisement